ES2301697T3 - Matrices de proteina modificada con factor de crecimiento para ingenieria de tejidos. - Google Patents

Matrices de proteina modificada con factor de crecimiento para ingenieria de tejidos. Download PDF

Info

Publication number: ES2301697T3
Authority: ES; Spain
Prior art keywords: baselineskip; matrix; pth; domain; fusion peptide
Prior art date: 2001-12-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES02792510T

Other languages

English (en)

Spanish (es)

Inventor

Jeffrey A. Hubbell

Matthias Lutolf

Jason Schense

Anna Jen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eidgenoessische Technische Hochschule Zurich ETHZ

Zurich Universitaet Institut fuer Medizinische Virologie

Original Assignee

Eidgenoessische Technische Hochschule Zurich ETHZ

Zurich Universitaet Institut fuer Medizinische Virologie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-18

Filing date

2002-12-18

Publication date

2008-07-01

2001-12-18 Priority claimed from US10/024,918 external-priority patent/US20020168718A1/en

2002-11-07 Priority claimed from PCT/EP2002/012458 external-priority patent/WO2003040235A1/en

2002-12-17 Priority claimed from US10/323,046 external-priority patent/US7601685B2/en

2002-12-18 Application filed by Eidgenoessische Technische Hochschule Zurich ETHZ, Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Eidgenoessische Technische Hochschule Zurich ETHZ

2008-07-01 Application granted granted Critical

2008-07-01 Publication of ES2301697T3 publication Critical patent/ES2301697T3/es

2022-12-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

102000035118 modified proteins Human genes 0.000 title description 3
108091005573 modified proteins Proteins 0.000 title description 3
239000003102 growth factor Substances 0.000 title description 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 118
239000000758 substrate Substances 0.000 claims abstract description 50
230000004927 fusion Effects 0.000 claims abstract description 42
239000011159 matrix material Substances 0.000 claims description 122
239000002243 precursor Substances 0.000 claims description 96
229920001223 polyethylene glycol Polymers 0.000 claims description 59
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 58
108010073385 Fibrin Proteins 0.000 claims description 57
102000009123 Fibrin Human genes 0.000 claims description 56
229950003499 fibrin Drugs 0.000 claims description 56
239000002202 Polyethylene glycol Substances 0.000 claims description 52
238000006731 degradation reaction Methods 0.000 claims description 50
230000015556 catabolic process Effects 0.000 claims description 47
108010049003 Fibrinogen Proteins 0.000 claims description 34
102000008946 Fibrinogen Human genes 0.000 claims description 34
229940012952 fibrinogen Drugs 0.000 claims description 34
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims description 29
235000018102 proteins Nutrition 0.000 claims description 27
102000004169 proteins and genes Human genes 0.000 claims description 27
108090000623 proteins and genes Proteins 0.000 claims description 27
102000004190 Enzymes Human genes 0.000 claims description 21
108090000790 Enzymes Proteins 0.000 claims description 21
108090000190 Thrombin Proteins 0.000 claims description 21
229940088598 enzyme Drugs 0.000 claims description 21
150000003573 thiols Chemical class 0.000 claims description 21
229960004072 thrombin Drugs 0.000 claims description 21
108010000196 Factor XIIIa Proteins 0.000 claims description 18
238000000034 method Methods 0.000 claims description 18
239000000463 material Substances 0.000 claims description 15
108060008539 Transglutaminase Proteins 0.000 claims description 14
230000000269 nucleophilic effect Effects 0.000 claims description 14
102000003601 transglutaminase Human genes 0.000 claims description 14
229940012957 plasmin Drugs 0.000 claims description 13
239000003153 chemical reaction reagent Substances 0.000 claims description 12
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
235000018417 cysteine Nutrition 0.000 claims description 12
238000007259 addition reaction Methods 0.000 claims description 11
150000001412 amines Chemical class 0.000 claims description 9
230000000593 degrading effect Effects 0.000 claims description 9
230000002255 enzymatic effect Effects 0.000 claims description 9
230000012010 growth Effects 0.000 claims description 9
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
239000011575 calcium Substances 0.000 claims description 6
229910052791 calcium Inorganic materials 0.000 claims description 6
230000003301 hydrolyzing effect Effects 0.000 claims description 5
230000010261 cell growth Effects 0.000 claims description 4
102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
108090000445 Parathyroid hormone Proteins 0.000 description 95
102000003982 Parathyroid hormone Human genes 0.000 description 94
239000000199 parathyroid hormone Substances 0.000 description 94
229960001319 parathyroid hormone Drugs 0.000 description 94
210000004027 cell Anatomy 0.000 description 63
239000000499 gel Substances 0.000 description 50
230000007547 defect Effects 0.000 description 47
230000035876 healing Effects 0.000 description 40
210000000988 bone and bone Anatomy 0.000 description 36
239000000243 solution Substances 0.000 description 33
102000004196 processed proteins & peptides Human genes 0.000 description 28
238000006243 chemical reaction Methods 0.000 description 26
241000282414 Homo sapiens Species 0.000 description 24
239000000203 mixture Substances 0.000 description 24
229920000642 polymer Polymers 0.000 description 24
230000004044 response Effects 0.000 description 24
210000001519 tissue Anatomy 0.000 description 24
230000015572 biosynthetic process Effects 0.000 description 23
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
230000000694 effects Effects 0.000 description 20
125000000524 functional group Chemical group 0.000 description 20
238000010348 incorporation Methods 0.000 description 18
239000000017 hydrogel Substances 0.000 description 16
210000000963 osteoblast Anatomy 0.000 description 15
239000012620 biological material Substances 0.000 description 14
102000005962 receptors Human genes 0.000 description 14
108020003175 receptors Proteins 0.000 description 14
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 13
241001494479 Pecora Species 0.000 description 13
238000001879 gelation Methods 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
230000000975 bioactive effect Effects 0.000 description 12
238000002156 mixing Methods 0.000 description 12
150000001413 amino acids Chemical group 0.000 description 11
239000012038 nucleophile Substances 0.000 description 10
108010085895 Laminin Proteins 0.000 description 9
102000007547 Laminin Human genes 0.000 description 9
108091005804 Peptidases Proteins 0.000 description 9
239000004365 Protease Substances 0.000 description 9
239000000872 buffer Substances 0.000 description 9
108020001507 fusion proteins Proteins 0.000 description 9
102000037865 fusion proteins Human genes 0.000 description 9
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 8
108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
230000008595 infiltration Effects 0.000 description 8
238000001764 infiltration Methods 0.000 description 8
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 7
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
230000012292 cell migration Effects 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
210000002997 osteoclast Anatomy 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
230000017854 proteolysis Effects 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
150000001252 acrylic acid derivatives Chemical class 0.000 description 6
238000006482 condensation reaction Methods 0.000 description 6
238000002513 implantation Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
230000002797 proteolythic effect Effects 0.000 description 6
238000011069 regeneration method Methods 0.000 description 6
238000007634 remodeling Methods 0.000 description 6
230000008439 repair process Effects 0.000 description 6
MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical group NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 description 5
241000700159 Rattus Species 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
230000001588 bifunctional effect Effects 0.000 description 5
230000021164 cell adhesion Effects 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
230000015271 coagulation Effects 0.000 description 5
238000005345 coagulation Methods 0.000 description 5
230000002950 deficient Effects 0.000 description 5
230000004069 differentiation Effects 0.000 description 5
150000004662 dithiols Chemical class 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000008187 granular material Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000011065 in-situ storage Methods 0.000 description 5
239000003446 ligand Substances 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
238000006116 polymerization reaction Methods 0.000 description 5
230000008929 regeneration Effects 0.000 description 5
230000007017 scission Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
102000008186 Collagen Human genes 0.000 description 4
108010067306 Fibronectins Proteins 0.000 description 4
102000016359 Fibronectins Human genes 0.000 description 4
101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 4
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
239000006096 absorbing agent Substances 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000009471 action Effects 0.000 description 4
230000037182 bone density Effects 0.000 description 4
230000010072 bone remodeling Effects 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
238000013461 design Methods 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
238000005553 drilling Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000012039 electrophile Substances 0.000 description 4
230000007515 enzymatic degradation Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
102000058004 human PTH Human genes 0.000 description 4
230000006872 improvement Effects 0.000 description 4
229940100601 interleukin-6 Drugs 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
230000005012 migration Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
239000000178 monomer Substances 0.000 description 4
230000011164 ossification Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
230000035939 shock Effects 0.000 description 4
-1 succinimidyl group Chemical group 0.000 description 4
125000003396 thiol group Chemical group [H]S* 0.000 description 4
XQQUSYWGKLRJRA-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XQQUSYWGKLRJRA-RABCQHRBSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
108010071289 Factor XIII Proteins 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 3
230000021736 acetylation Effects 0.000 description 3
238000006640 acetylation reaction Methods 0.000 description 3
230000009435 amidation Effects 0.000 description 3
238000007112 amidation reaction Methods 0.000 description 3
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
235000011148 calcium chloride Nutrition 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
239000008380 degradant Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229940012444 factor xiii Drugs 0.000 description 3
108010053299 glycyl-arginyl-glycyl-aspartyl-seryl-proline Proteins 0.000 description 3
210000002758 humerus Anatomy 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
102000006495 integrins Human genes 0.000 description 3
108010044426 integrins Proteins 0.000 description 3
230000003993 interaction Effects 0.000 description 3
108010088381 isoleucyl-lysyl-valyl-alanyl-valine Proteins 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000017423 tissue regeneration Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
210000000689 upper leg Anatomy 0.000 description 3
229920002554 vinyl polymer Polymers 0.000 description 3
NTEDOEBWPRVVSG-XUXIUFHCSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(O)=O NTEDOEBWPRVVSG-XUXIUFHCSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
KFDVPJUYSDEJTH-UHFFFAOYSA-O 4-ethenylpyridine;hydron Chemical compound C=CC1=CC=[NH+]C=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-O 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
NNMUHYLAYUSTTN-FXQIFTODSA-N Asn-Gln-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O NNMUHYLAYUSTTN-FXQIFTODSA-N 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 2
JBRBACJPBZNFMF-YUMQZZPRSA-N Gly-Ala-Lys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN JBRBACJPBZNFMF-YUMQZZPRSA-N 0.000 description 2
YZACQYVWLCQWBT-BQBZGAKWSA-N Gly-Cys-Arg Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O YZACQYVWLCQWBT-BQBZGAKWSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108010067372 Pancreatic elastase Proteins 0.000 description 2
102000016387 Pancreatic elastase Human genes 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
102000013566 Plasminogen Human genes 0.000 description 2
108010051456 Plasminogen Proteins 0.000 description 2
241001415846 Procellariidae Species 0.000 description 2
150000003926 acrylamides Chemical class 0.000 description 2
HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
102000003801 alpha-2-Antiplasmin Human genes 0.000 description 2
108090000183 alpha-2-Antiplasmin Proteins 0.000 description 2
230000001195 anabolic effect Effects 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000010478 bone regeneration Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
230000008614 cellular interaction Effects 0.000 description 2
230000033077 cellular process Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
239000007943 implant Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
238000011835 investigation Methods 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
239000012705 liquid precursor Substances 0.000 description 2
108010003700 lysyl aspartic acid Proteins 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000005022 packaging material Substances 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
230000000379 polymerizing effect Effects 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000000746 purification Methods 0.000 description 2
150000004053 quinones Chemical class 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000012552 review Methods 0.000 description 2
239000000565 sealant Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000003068 static effect Effects 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
108010052768 tyrosyl-isoleucyl-glycyl-seryl-arginine Proteins 0.000 description 2
XBMQRPDOXIPUFG-HNNXBMFYSA-N (2s)-2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-4-methylpentanoic acid Chemical compound C1=CC=C2C(S(=O)(=O)N[C@@H](CC(C)C)C(O)=O)=CC=CC2=C1N(C)C XBMQRPDOXIPUFG-HNNXBMFYSA-N 0.000 description 1
RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 description 1
NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
HZHXMUPSBUKRBW-FXQIFTODSA-N (4s)-4-[[2-[[(2s)-2-amino-3-carboxypropanoyl]amino]acetyl]amino]-5-[[(1s)-1-carboxyethyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O HZHXMUPSBUKRBW-FXQIFTODSA-N 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
125000000981 3-amino-3-oxopropyl group Chemical group [H]C([*])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
GGNHBHYDMUDXQB-KBIXCLLPSA-N Ala-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)N GGNHBHYDMUDXQB-KBIXCLLPSA-N 0.000 description 1
QPOARHANPULOTM-GMOBBJLQSA-N Arg-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N QPOARHANPULOTM-GMOBBJLQSA-N 0.000 description 1
ICAYWNTWHRRAQP-FXQIFTODSA-N Asp-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N)CN=C(N)N ICAYWNTWHRRAQP-FXQIFTODSA-N 0.000 description 1
POTCZYQVVNXUIG-BQBZGAKWSA-N Asp-Gly-Pro Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 description 1
KBJVTFWQWXCYCQ-IUKAMOBKSA-N Asp-Thr-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KBJVTFWQWXCYCQ-IUKAMOBKSA-N 0.000 description 1
108010027612 Batroxobin Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101001135732 Bos taurus Parathyroid hormone Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
241001125671 Eretmochelys imbricata Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
BTSPOOHJBYJRKO-CIUDSAMLSA-N Gln-Asp-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BTSPOOHJBYJRKO-CIUDSAMLSA-N 0.000 description 1
GPISLLFQNHELLK-DCAQKATOSA-N Gln-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N GPISLLFQNHELLK-DCAQKATOSA-N 0.000 description 1
GNMQDOGFWYWPNM-LAEOZQHASA-N Gln-Gly-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(O)=O GNMQDOGFWYWPNM-LAEOZQHASA-N 0.000 description 1
HTTSBEBKVNEDFE-AUTRQRHGSA-N Glu-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N HTTSBEBKVNEDFE-AUTRQRHGSA-N 0.000 description 1
CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical compound [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 1
XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 1
CVFOYJJOZYYEPE-KBPBESRZSA-N Gly-Lys-Tyr Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CVFOYJJOZYYEPE-KBPBESRZSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
RMNMUUCYTMLWNA-ZPFDUUQYSA-N Ile-Lys-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N RMNMUUCYTMLWNA-ZPFDUUQYSA-N 0.000 description 1
WKSHBPRUIRGWRZ-KCTSRDHCSA-N Ile-Trp-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N WKSHBPRUIRGWRZ-KCTSRDHCSA-N 0.000 description 1
102100022746 Laminin subunit alpha-1 Human genes 0.000 description 1
101710200522 Laminin subunit alpha-1 Proteins 0.000 description 1
KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 1
RFUBXQQFJFGJFV-GUBZILKMSA-N Leu-Asn-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RFUBXQQFJFGJFV-GUBZILKMSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000006735 Periostitis Diseases 0.000 description 1
108090000316 Pitrilysin Proteins 0.000 description 1
SGCZFWSQERRKBD-BQBZGAKWSA-N Pro-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 SGCZFWSQERRKBD-BQBZGAKWSA-N 0.000 description 1
ZPPVJIJMIKTERM-YUMQZZPRSA-N Pro-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ZPPVJIJMIKTERM-YUMQZZPRSA-N 0.000 description 1
108010054530 RGDN peptide Proteins 0.000 description 1
RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 1
AKXBNSZMYAOGLS-STQMWFEESA-N Tyr-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AKXBNSZMYAOGLS-STQMWFEESA-N 0.000 description 1
PMDWYLVWHRTJIW-STQMWFEESA-N Tyr-Gly-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PMDWYLVWHRTJIW-STQMWFEESA-N 0.000 description 1
GITNQBVCEQBDQC-KKUMJFAQSA-N Tyr-Lys-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O GITNQBVCEQBDQC-KKUMJFAQSA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
150000008360 acrylonitriles Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
108010060035 arginylproline Proteins 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
108010027234 aspartyl-glycyl-glutamyl-alanine Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000003592 biomimetic effect Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
230000014461 bone development Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000004956 cell adhesive effect Effects 0.000 description 1
230000008619 cell matrix interaction Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229960005188 collagen Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
108010016616 cysteinylglycine Proteins 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
210000003275 diaphysis Anatomy 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000002745 epiphysis Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
108010010147 glycylglutamine Proteins 0.000 description 1
230000036541 health Effects 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
108010028295 histidylhistidine Proteins 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000010952 in-situ formation Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
CTCHDPAJHVDPRN-UHFFFAOYSA-N integrin Chemical compound C=1C(OC)=CC(O)=C(C(C=2CC=C(C)C)=O)C=1OC=2C1=CC=C(O)C=C1O CTCHDPAJHVDPRN-UHFFFAOYSA-N 0.000 description 1
230000017306 interleukin-6 production Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical class CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000001002 morphogenetic effect Effects 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
108091005763 multidomain proteins Proteins 0.000 description 1
239000005445 natural material Substances 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000009689 neuronal regeneration Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
OKXGHXHZNCJMSV-UHFFFAOYSA-N nitro phenyl carbonate Chemical compound [O-][N+](=O)OC(=O)OC1=CC=CC=C1 OKXGHXHZNCJMSV-UHFFFAOYSA-N 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
229920002601 oligoester Polymers 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000002990 parathyroid gland Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
210000003460 periosteum Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001444 polymaleic acid Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000009822 protein phosphorylation Effects 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
238000010526 radical polymerization reaction Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000001338 self-assembly Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
108091006024 signal transducing proteins Proteins 0.000 description 1
102000034285 signal transducing proteins Human genes 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
150000007944 thiolates Chemical class 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012876 topography Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Transplantation (AREA)
Oral & Maxillofacial Surgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Orthopedic Medicine & Surgery (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Materials For Medical Uses (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

ES02792510T 2001-12-18 2002-12-18 Matrices de proteina modificada con factor de crecimiento para ingenieria de tejidos. Expired - Lifetime ES2301697T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US24918		2001-12-18
US10/024,918 US20020168718A1 (en)	1997-04-03	2001-12-18	Enzyme-mediated modification of fibrin for tissue engineering
WOPCT/EP02/12458		2002-11-07
PCT/EP2002/012458 WO2003040235A1 (en)	2001-11-07	2002-11-07	Synthetic matrix for controlled cell ingrowth and tissue regeneration
US10/323,046 US7601685B2 (en)	1998-08-27	2002-12-17	Growth factor modified protein matrices for tissue engineering
US323046		2002-12-17

Publications (1)

Publication Number	Publication Date
ES2301697T3 true ES2301697T3 (es)	2008-07-01

Family

ID=27807134

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES02792510T Expired - Lifetime ES2301697T3 (es)	2001-12-18	2002-12-18	Matrices de proteina modificada con factor de crecimiento para ingenieria de tejidos.

Country Status (9)

Country	Link
JP (2)	JP4560291B2 (ja)
AT (1)	ATE386545T1 (ja)
AU (2)	AU2002358272B2 (ja)
BR (1)	BRPI0215192B8 (ja)
CA (1)	CA2470419A1 (ja)
DE (1)	DE60225185T2 (ja)
ES (1)	ES2301697T3 (ja)
MX (1)	MXPA04006021A (ja)
WO (1)	WO2003052091A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7351423B2 (en)	2004-09-01	2008-04-01	Depuy Spine, Inc.	Musculo-skeletal implant having a bioactive gradient
EP1862170B1 (en)	2004-12-10	2012-03-14	Straumann Holding AG	Enamel formulation with amelogenin
EP2329832A1 (en)	2004-12-10	2011-06-08	Straumann Holding AG	Protein formulation
SE0403014D0 (sv)	2004-12-10	2004-12-10	Straumann Holding Ag	New protein formulation
JP2008529972A (ja) *	2004-12-22	2008-08-07	クロス・バイオサージェリー・アクチェンゲゼルシャフト	酵素的に分解可能な連結を通じて生物活性因子が組み入れられている合成バイオマテリアル
WO2006073711A2 (en) *	2005-01-06	2006-07-13	Kuros Biosurgery Ag	Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en)	2005-01-06	2013-11-05	Kuros Biosurgery Ag	Supplemented matrices for the repair of bone fractures
ES2593051T3 (es) *	2005-01-06	2016-12-05	Kuros Biosurgery Ag	Matrices suplementadas para la reparación de fracturas óseas
CA2683862C (en)	2007-04-09	2016-08-02	The Board Of Trustees Of The University Of Arkansas	Fusion protein of collagen-binding domain and parathyroid hormone
PT2136850E (pt)	2007-04-13	2012-04-27	Kuros Biosurgery Ag	Selante tecidual polimérico
WO2009047361A2 (en) *	2007-10-12	2009-04-16	Kuros Biosurgery Ag	Injectable fibrin compositions for tissue augmentation comprising strontium salt
JP2011516228A (ja)	2008-04-18	2011-05-26	クロス・バイオサージェリー・アクチェンゲゼルシャフト	分配装置、分配装置を含むキット、および分配装置を動作させる方法
WO2011025957A2 (en) *	2009-08-28	2011-03-03	Ecole Polytechnique Federal De Lausanne	Tg-aprotinin fusion proteins and matrices thereof
EP2670856B1 (en) *	2011-02-03	2018-06-27	Northeastern University	Methods and compositions for highly specific capture and release of biological materials
WO2012123028A1 (en)	2011-03-16	2012-09-20	Kuros Biosurgery Ag	Pharmaceutical formulation for use in spinal fusion
WO2013120060A1 (en)	2012-02-09	2013-08-15	The Board Of Trustees Of The University Of Arkansas	Delivery of therapeutic agents by a collagen binding protein
CA3113972C (en)	2011-12-14	2023-08-01	The Board Of Trustees Of The University Of Arkansas	Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments
US9790264B2 (en)	2012-06-25	2017-10-17	The Brigham And Women's Hospital, Inc.	Compounds and methods for modulating pharmacokinetics
ES2651113T3 (es)	2012-06-25	2018-01-24	The Brigham And Women's Hospital, Inc.	Tratamientos terapéuticos dirigidos
HUE055937T2 (hu) *	2015-09-09	2022-01-28	Eth Zuerich	Injektálható makroporózus hidrogélek
US11624060B2 (en)	2017-02-10	2023-04-11	The Board Of Trustees Of The University Of Arkansas	Collagen-binding agent compositions and methods of using the same
EP3536353A1 (en)	2018-03-09	2019-09-11	Kuros Biosurgery AG	Method and kits for producing a fibrin matrix
US12403179B2 (en)	2021-02-18	2025-09-02	The Board Of Trustees Of The University Of Arkansas	Release of growth factors at wound healing stages

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5171670A (en) *	1989-05-12	1992-12-15	The General Hospital Corporation	Recombinant dna method for production of parathyroid hormone
US5589452A (en) *	1992-07-14	1996-12-31	Syntex (U.S.A.) Inc.	Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
WO1997018314A1 (de) *	1995-11-16	1997-05-22	Boehringer Mannheim Gmbh	Verfahren zur herstellung von peptiden über streptavidin-fusionsproteine
JP2002508395A (ja) *	1997-12-18	2002-03-19	イーライ・リリー・アンド・カンパニー	結晶テリパラチド
AU773914B2 (en) *	1999-02-01	2004-06-10	Eidgenossische Technische Hochschule Zurich	Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
JP2001190280A (ja) *	1999-02-19	2001-07-17	Terumo Corp	コラーゲン結合性生理活性ポリペプチド

2002
- 2002-12-18 MX MXPA04006021A patent/MXPA04006021A/es active IP Right Grant
- 2002-12-18 WO PCT/US2002/041114 patent/WO2003052091A1/en not_active Ceased
- 2002-12-18 JP JP2003552958A patent/JP4560291B2/ja not_active Expired - Lifetime
- 2002-12-18 AT AT02792510T patent/ATE386545T1/de not_active IP Right Cessation
- 2002-12-18 DE DE60225185T patent/DE60225185T2/de not_active Expired - Lifetime
- 2002-12-18 ES ES02792510T patent/ES2301697T3/es not_active Expired - Lifetime
- 2002-12-18 BR BRPI0215192A patent/BRPI0215192B8/pt not_active IP Right Cessation
- 2002-12-18 AU AU2002358272A patent/AU2002358272B2/en not_active Expired
- 2002-12-18 CA CA002470419A patent/CA2470419A1/en not_active Abandoned
2009
- 2009-01-13 JP JP2009005240A patent/JP2009102383A/ja active Pending
- 2009-04-21 AU AU2009201588A patent/AU2009201588B2/en not_active Expired

Also Published As

Publication number	Publication date
BRPI0215192B8 (pt)	2021-07-27
AU2009201588B2 (en)	2011-02-24
JP2009102383A (ja)	2009-05-14
MXPA04006021A (es)	2005-08-19
DE60225185D1 (de)	2008-04-03
AU2002358272A1 (en)	2003-06-30
BRPI0215192B1 (pt)	2016-03-22
JP2005517658A (ja)	2005-06-16
CA2470419A1 (en)	2003-06-26
WO2003052091A1 (en)	2003-06-26
AU2002358272B2 (en)	2009-01-22
WO2003052091A8 (en)	2003-08-07
AU2009201588A1 (en)	2009-05-14
DE60225185T2 (de)	2009-02-19
JP4560291B2 (ja)	2010-10-13
BR0215192A (pt)	2005-04-26
ATE386545T1 (de)	2008-03-15

Publication	Publication Date	Title
ES2301697T3 (es)	2008-07-01	Matrices de proteina modificada con factor de crecimiento para ingenieria de tejidos.
US8034618B2 (en)	2011-10-11	PTH containing cell growth matrix
ES2476996T3 (es)	2014-07-15	Tratamiento local de defectos óseos con matriz de liberación de PTH
ES2368988T3 (es)	2011-11-24	Bio-materiales formados por reacción de adición nucleófila a grupos insaturados conjugados.
ES2321068T3 (es)	2009-06-02	Matrices de suministro de farmacos para mejorar la curacion de heridas.
ES2451651T3 (es)	2014-03-28	Composiciones de liberación inmediata para el tratamiento de daños tisulares
KR101054023B1 (ko)	2011-08-04	세포 내증식 및 조직 재생을 제어하기 위한 합성 매트릭스
ES2902872T3 (es)	2022-03-30	Matrices suplementadas para la reparación de fracturas óseas
EP1465989B1 (en)	2008-02-20	Growth factor modified protein matrices for tissue engineering
KR100925070B1 (ko)	2009-11-04	성장인자로 변형된 조직 엔지니어링용 단백질 메트릭스
EP1864681A1 (en)	2007-12-12	Growth factor modified protein matrices for tissue engineering
HK1067147B (en)	2008-07-18	Growth factor modified protein matrices for tissue engineering
EP1837040A2 (en)	2007-09-26	Drug delivery matrices to enhance wound healing
CN101098717A (zh)	2008-01-02	用于修复骨折的补充的基质